Eneda Toska

Research output

Research output per year 2011 2014 2017 2019 2020 2021 2024

• 33 Article
• 6 Review article
• 5 Comment/debate
• 1 Chapter

Research output per year

Research output per year

Search results

• 2024

  ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma

  Jagirdar, K., Portuallo, M. E., Wei, M., Wilhide, M., Bravo Narula, J. A., Robertson, B. M., Alicea, G. M., Aguh, C., Xiao, M., Godok, T., Fingerman, D., Brown, G. S., Herlyn, M., Elad, V. M., Guo, X., Toska, E., Zabransky, D. J., Wubbenhorst, B., Nathanson, K. L., Kwatra, S., & 4 othersGoyal, Y., Ji, H., Liu, Q. & Rebecca, V. W., Feb 2 2024, In: Oncogene. 43, 6, p. 395-405 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cyclin-Dependent Kinase 6 100%
  • Cyclin-Dependent Kinase 4 91%
  • Melanoma 53%
  • Extremities 48%
  • Heterografts 14%
• 2023

  Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer

  Bianchi, A., Silva, I. D. C., Deshpande, N. U., Singh, S., Mehra, S., Garrido, V. T., Guo, X., Nivelo, L. A., Kolonias, D. S., Saigh, S. J., Wieder, E., Rafie, C. I., Dosch, A. R., Zhou, Z., Umland, O., Amirian, H., Ogobuiro, I. C., Zhang, J., Ban, Y., Shiau, C., & 11 othersNagathihalli, N. S., Montgomery, E. A., Hwang, W. L., Brambilla, R., Komanduri, K., Villarino, A. V., Toska, E., Stanger, B. Z., Gabrilovich, D. I., Merchant, N. B. & Datta, J., Jun 1 2023, In: Cancer discovery. 13, 6, p. 1428-1453 26 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Pancreatic Neoplasms 100%
  • Neutrophils 82%
  • Cancer-Associated Fibroblasts 73%
  • Inflammation 62%
  • Adenocarcinoma 62%
• 2022

  A Unique FOXA1-Associated Chromatin State Dictates Therapeutic Resistance in Lobular Breast Cancer

  Blawski, R. & Toska, E., Oct 15 2022, In: Cancer Research. 82, 20, p. 3668-3670 3 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chromatin 64%
  • Breast Neoplasms 46%
  • Ductal Carcinoma 22%
  • Estrogen Receptors 17%
  • Therapeutics 11%

• The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation

  Ladewig, E., Michelini, F., Jhaveri, K., Castel, P., Carmona, J., Fairchild, L., Zuniga, A. G., Arruabarrena-Aristorena, A., Cocco, E., Blawski, R., Kittane, S., Zhang, Y., Sallaku, M., Baldino, L., Hristidis, V., Chandarlapaty, S., Abdel-Wahab, O., Leslie, C., Scaltriti, M. & Toska, E., Jun 15 2022, In: Cancer Research. 82, 12, p. 2269-2280 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Gene Expression Regulation 100%
  • Phosphatidylinositols 98%
  • Alpelisib 38%
  • Breast Neoplasms 32%
  • RNA Splicing 27%
• 2021

  Cholesterol is required for transcriptional repression by BASP1

  Loats, A. E., Carrera, S., Fleming, A. F., Roberts, A. R. E., Sherrard, A., Toska, E., Moorhouse, A. J., Medler, K. F. & Roberts, S. G. E., Jul 20 2021, In: Proceedings of the National Academy of Sciences of the United States of America. 118, 29, e2101671118.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Acids 100%
  • Cholesterol 97%
  • Brain 64%
  • Proteins 48%
  • Wilms Tumor 45%

• Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit the sensitivity to PI3Ka inhibitors

  Cai, Y., Xu, G., Wu, F., Michelini, F., Chan, C., Qu, X., Selenica, P., Ladewig, E., Castel, P., Cheng, Y., Zhao, A., Jhaveri, K., Toska, E., Jimenez, M., Jacquet, A., Tran-Dien, A., Andre, F., Chandarlapaty, S., Reis-Filho, J. S., Razavi, P., & 1 othersScaltriti, M., May 1 2021, In: Cancer Research. 81, 9, p. 2470-2780 311 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mechanistic Target of Rapamycin Complex 1 100%
  • Breast Neoplasms 50%
  • Clustered Regularly Interspaced Short Palindromic Repeats 45%
  • Estrogen Receptors 37%
  • Genes 32%

• José Baselga (1959-2021)

  Castel, P., Toska, E., Vasan, N., Cocco, E. & Scaltriti, M., May 10 2021, In: Cancer cell. 39, 5, p. 581-582 2 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Josep Baselga (1959-2021)

  Castel, P. & Toska, E., Jun 24 2021, In: Cell. 184, 13, p. 3349-3351 3 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• TRK XDFG mutations trigger a sensitivity switch from type i to ii kinase inhibitors

  Cocco, E., Lee, J. E., Kannan, S., Schram, A. M., Won, H. H., Shifman, S., Kulick, A., Baldino, L., Toska, E., Arruabarrena-Aristorena, A., Kittane, S., Wu, F., Cai, Y., Arena, S., Mussolin, B., Kannan, R., Vasan, N., Gorelick, A. N., Berger, M. F., Novoplansky, O., & 14 othersJagadeeshan, S., Liao, Y., Rix, U., Misale, S., Taylor, B. S., Bardelli, A., Hechtman, J. F., Hyman, D. M., Elkabets, M., de Stanchina, E., Verma, C. S., Ventura, A., Drilon, A. & Scaltriti, M., Jan 2021, In: Cancer discovery. 11, 1, p. 126-141 16 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Phosphotransferases 100%
  • Drug Design 74%
  • Mutation 72%
  • Drug Substitution 47%
  • Immunoglobulin Class Switching 45%

• UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth

  Wolfe, A. L., Zhou, Q., Toska, E., Galeas, J., Ku, A. A., Koche, R. P., Bandyopadhyay, S., Scaltriti, M., Lebrilla, C. B., McCormick, F. & Kim, S. E., Aug 3 2021, In: Proceedings of the National Academy of Sciences of the United States of America. 118, 31, e2103592118.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • UTP-Glucose-1-Phosphate Uridylyltransferase 100%
  • Uridine Diphosphate Glucose 82%
  • Glycogen 56%
  • Glycosylation 56%
  • Pancreatic Neoplasms 51%
• 2020

  ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer

  Xu, G., Chhangawala, S., Cocco, E., Razavi, P., Cai, Y., Otto, J. E., Ferrando, L., Selenica, P., Ladewig, E., Chan, C., Da Cruz Paula, A., Witkin, M., Cheng, Y., Park, J., Serna-Tamayo, C., Zhao, H. Y., Wu, F., Sallaku, M., Qu, X., Zhao, A., & 11 othersCollings, C. K., D’Avino, A. R., Jhaveri, K., Koche, R., Levine, R. L., Reis-Filho, J. S., Kadoch, C., Scaltriti, M., Leslie, C. S., Baselga, J. & Toska, E., Feb 1 2020, In: Nature genetics. 52, 2, p. 198-207 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Estrogen Receptors 100%
  • Breast Neoplasms 68%
  • Hepatocyte Nuclear Factor 3-alpha 66%
  • GATA3 Transcription Factor 61%
  • Fulvestrant 47%

• FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer

  Arruabarrena-Aristorena, A., Maag, J. L. V., Kittane, S., Cai, Y., Karthaus, W. R., Ladewig, E., Park, J., Kannan, S., Ferrando, L., Cocco, E., Ho, S. Y., Tan, D. S., Sallaku, M., Wu, F., Acevedo, B., Selenica, P., Ross, D. S., Witkin, M., Sawyers, C. L., Reis-Filho, J. S., & 7 othersVerma, C. S., Jauch, R., Koche, R., Baselga, J., Razavi, P., Toska, E. & Scaltriti, M., Oct 12 2020, In: Cancer cell. 38, 4, p. 534-550.e9

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chromatin 100%
  • Breast Neoplasms 72%
  • Mutation 63%
  • Nucleotide Motifs 24%
  • Aromatase Inhibitors 23%

• Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma

  Mondello, P., Tadros, S., Teater, M., Fontan, L., Chang, A. Y., Jain, N., Yang, H., Singh, S., Ying, H. Y., Chu, C. S., Ma, M. C. J., Toska, E., Alig, S., Durant, M., de Stanchina, E., Ghosh, S., Mottok, A., Nastoupil, L., Neelapu, S. S., Weigert, O., & 9 othersInghirami, G., Baselga, J., Younes, A., Yee, C., Dogan, A., Scheinberg, D. A., Roeder, R. G., Melnick, A. M. & Green, M. R., Mar 2020, In: Cancer discovery. 10, 3, p. 440-459 20 p.

  Research output: Contribution to journal › Article › peer-review

  • Lymphoma 100%
  • Histone Acetyltransferases 79%
  • Mutation 67%
  • Epigenomics 52%
  • Genes 48%
• 2019

  Chromatin regulation at the intersection of estrogen receptor and PI3K pathways in breast cancer

  Castel, P. & Toska, E., Nov 2 2019, In: Molecular and Cellular Oncology. 6, 6, e1625620.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Phosphatidylinositol 3-Kinase 100%
  • Estrogen Receptors 92%
  • Chromatin 87%
  • Breast Neoplasms 62%
  • serum-glucocorticoid regulated kinase 56%

• Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Ka inhibitors

  Vasan, N., Razavi, P., Johnson, J. L., Shao, H., Shah, H., Antoine, A., Ladewig, E., Gorelick, A., Lin, T. Y., Toska, E., Xu, G., Kazmi, A., Chang, M. T., Taylor, B. S., Dickler, M. N., Jhaveri, K., Chandarlapaty, S., Rabadan, R., Reznik, E., Smith, M. L., & 7 othersSebra, R., Schimmoller, F., Wilson, T. R., Friedman, L. S., Cantley, L. C., Scaltriti, M. & Baselga, J., Nov 8 2019, In: Science. 366, 6466, p. 714-723 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Phosphoinositide-3 Kinase Inhibitors 100%
  • Mutation 39%
  • Breast Cancer 3 14%
  • Membrane Lipids 11%
  • Phosphatidylinositol 3-Kinases 9%

• PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression

  Toska, E., Castel, P., Chhangawala, S., Arruabarrena-Aristorena, A., Chan, C., Hristidis, V. C., Cocco, E., Sallaku, M., Xu, G., Park, J., Minuesa, G., Shifman, S. G., Socci, N. D., Koche, R., Leslie, C. S., Scaltriti, M. & Baselga, J., Apr 2 2019, In: Cell Reports. 27, 1, p. 294-306.e5

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Estrogen 100%
  • Phosphatidylinositol 3-Kinases 92%
  • Estrogen Receptors 87%
  • Chromatin 82%
  • Gene Expression 55%

• Resistance to TRK inhibition mediated by convergent MAPK pathway activation

  Cocco, E., Schram, A. M., Kulick, A., Misale, S., Won, H. H., Yaeger, R., Razavi, P., Ptashkin, R., Hechtman, J. F., Toska, E., Cownie, J., Somwar, R., Shifman, S., Mattar, M., Selçuklu, S. D., Samoila, A., Guzman, S., Tuch, B. B., Ebata, K., de Stanchina, E., & 9 othersNagy, R. J., Lanman, R. B., Houck-Loomis, B., Patel, J. A., Berger, M. F., Ladanyi, M., Hyman, D. M., Drilon, A. & Scaltriti, M., Sep 1 2019, In: Nature medicine. 25, 9, p. 1422-1427 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Mitogen-Activated Protein Kinases 100%
  • Resistance 63%
  • ARRY-470 49%
  • Oncogenic 47%
  • Oncogene Addiction 42%
• 2018

  Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

  Cocco, E., Carmona, F. J., Razavi, P., Won, H. H., Cai, Y., Rossi, V., Chan, C., Cownie, J., Soong, J., Toska, E., Shifman, S. G., Sarotto, I., Savas, P., Wick, M. J., Papadopoulos, K. P., Moriarty, A., Cutler, R. E., Avogadri-Connors, F., Lalani, A. S., Bryce, R. P., & 9 othersChandarlapaty, S., Hyman, D. M., Solit, D. B., Boni, V., Loi, S., Baselga, J., Berger, M. F., Montemurro, F. & Scaltriti, M., Oct 9 2018, In: Science signaling. 11, 551, eaat9773.

  Research output: Contribution to journal › Article › peer-review

  • Neratinib 100%
  • N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide 87%
  • Mutation 42%
  • Lapatinib 32%
  • Breast Neoplasms 32%
• 2017

  Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs

  Osmanbeyoglu, H. U., Toska, E., Chan, C., Baselga, J. & Leslie, C. S., Jan 31 2017, In: Nature communications. 8, 14249.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • mutations 100%
  • cancer 80%
  • Mutation 72%
  • genes 50%
  • Drug 45%

• Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations

  Mondello, P., Brea, E. J., de Stanchina, E., Toska, E., Chang, A. Y., Fennell, M., Seshan, V., Garippa, R., Scheinberg, D. A., Baselga, J., Wendel, H. G. & Younes, A., Mar 23 2017, In: JCI Insight. 2, 6, e90196.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Panobinostat 100%
  • Lymphoma, Large B-Cell, Diffuse 70%
  • Histone Deacetylase Inhibitors 48%
  • Mutation 35%
  • Myeloid Differentiation Factor 88 15%

• PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D

  Toska, E., Osmanbeyoglu, H. U., Castel, P., Chan, C., Hendrickson, R. C., Elkabets, M., Dickler, M. N., Scaltriti, M., Leslie, C. S., Armstrong, S. A. & Baselga, J., Mar 24 2017, In: Science. 355, 6331, p. 1324-1330 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Phosphatidylinositol 3-Kinases 100%
  • Estrogen Receptors 94%
  • Epigenomics 88%
  • Breast Neoplasms 64%
  • Methyltransferases 28%

• TRI-tool: A web-tool for prediction of protein-protein interactions in human transcriptional regulation

  Perovic, V., Sumonja, N., Gemovic, B., Toska, E., Roberts, S. G. & Veljkovic, N., Jan 15 2017, In: Bioinformatics. 33, 2, p. 289-291 3 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Transcriptional Regulation 100%
  • Protein-protein Interaction 85%
  • Proteins 50%
  • Human 49%
  • Prediction 43%
• 2016

  PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition

  Castel, P., Ellis, H., Bago, R., Toska, E., Razavi, P., Carmona, F. J., Kannan, S., Verma, C. S., Dickler, M., Chandarlapaty, S., Brogi, E., Alessi, D. R., Baselga, J. & Scaltriti, M., Aug 8 2016, In: Cancer cell. 30, 2, p. 229-242 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mechanistic Target of Rapamycin Complex 1 100%
  • Phosphatidylinositol 3-Kinases 78%
  • Maintenance 11%
  • Phosphorylation 10%
  • Breast Neoplasms 10%

• Pharmacology in the era of targeted therapies: The case of PI3K inhibitors

  Toska, E. & Baselga, J., May 1 2016, In: Clinical Cancer Research. 22, 9, p. 2099-2101 3 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Phosphatidylinositol 3-Kinases 100%
  • Pharmacology 67%
  • Estrogen Receptor Modulators 43%
  • Estrogen Receptors 31%
  • Appointments and Schedules 27%
• 2015

  PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

  Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J. J., Spratt, D. E., Viola-Villegas, N. T., Castel, P., Minuesa, G., Morse, N., Rodón, J., Ibrahim, Y., Cortes, J., Perez-Garcia, J., Galvan, P., Grueso, J., Guzman, M., Katzenellenbogen, J. A., & 8 othersKharas, M., Lewis, J. S., Dickler, M., Serra, V., Rosen, N., Chandarlapaty, S., Scaltriti, M. & Baselga, J., Apr 15 2015, In: Science translational medicine. 7, 283, 283ra51.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Phosphatidylinositol 3-Kinase 100%
  • Estrogen Receptors 92%
  • Hormones 69%
  • Breast Neoplasms 62%
  • Fulvestrant 29%
  178 Scopus citations
• 2014

  Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation

  Busch, M., Schwindt, H., Brandt, A., Beier, M., Görldt, N., Romaniuk, P., Toska, E., Roberts, S., Royer, H. D. & Royer-Pokora, B., Aug 2014, In: Human molecular genetics. 23, 15, p. 3958-3974 17 p., ddu111.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Gain of Function Mutation 100%
  • cdc Genes 96%
  • Wilms Tumor 90%
  • Mutant Proteins 64%
  • Cell Proliferation 49%

• Presenilin influences glycogen synthase kinase-3 β (GSK-3β) for kinesin-1 and dynein function during axonal transport

  Dolma, K., Iacobucci, G. J., zheng, K. H., Shandilya, J., Toska, E., White, J. A., Spina, E. & Gunawardena, S., Mar 2014, In: Human molecular genetics. 23, 5, p. 1121-1133 13 p., ddt505.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Presenilins 100%
  • Glycogen Synthase Kinase 3 93%
  • Dyneins 91%
  • Kinesin 89%
  • Axonal Transport 86%

• Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment

  Castel, P., Toska, E., Zumsteg, Z. S., Carmona, F. J., Elkabets, M., Bosch, A. & Scaltriti, M., Sep 15 2014, In: Molecular and Cellular Oncology. 1, 3, e963447.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Phosphatidylinositol 3-Kinases 100%
  • Neoplasms 32%
  • Cell Survival 19%
  • Cell Proliferation 16%
  • Therapeutics 16%

• WT1 interacts with MAD2 and regulates mitotic checkpoint function

  Shandilya, J., Toska, E., Richard, D. J., Medler, K. F. & Roberts, S. G. E., 2014, In: Nature communications. 5, 4903.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Suppressor Factor 100%
  • suppressors 74%
  • M Phase Cell Cycle Checkpoints 70%
  • tumors 50%
  • mitosis 36%

• WT1 regulates the development of the posterior taste field

  Gao, Y., Toska, E., Denmon, D., Roberts, S. G. E. & Medler, K. F., Jun 2014, In: Development (Cambridge). 141, 11, p. 2271-2278 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Wilms Tumor 100%
  • Proteins 30%
  • Tongue 19%
  • Transcription Factors 15%
  • Bone Morphogenetic Protein 4 14%
• 2013

  Prohibitin is required for transcriptional repression by the WT1-BASP1 complex

  Toska, E., Shandilya, J., Goodfellow, S. J., Medler, K. F. & Roberts, S. G. E., Oct 28 2013, In: Oncogene. 33, 43, p. 5100-5108 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • prohibitin 100%
  • Wilms Tumor 76%
  • Proteins 23%
  • Chromatin Assembly and Disassembly 21%
  • Genetic Promoter Regions 17%
• 2012

  Repression of Transcription by WT1-BASP1 Requires the Myristoylation of BASP1 and the PIP2-Dependent Recruitment of Histone Deacetylase

  Toska, E., Campbell, H. A., Shandilya, J., Goodfellow, S. J., Shore, P., Medler, K. F. & Roberts, S. G. E., Sep 27 2012, In: Cell Reports. 2, 3, p. 462-469 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Myristoylation 100%
  • Histone Deacetylases 69%
  • Histone 63%
  • Co-Repressor Proteins 25%
  • Genes 23%
• 2011

  WT1 and its transcriptional cofactor BASP1 redirect the differentiation pathway of an established blood cell line

  Goodfellow, S. J., Rebello, M. R., Toska, E., Zeef, L. A. H., Rudd, S. G., Medler, K. F. & Roberts, S. G. E., Apr 1 2011, In: Biochemical Journal. 435, 1, p. 113-125 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Wilms Tumor 100%
  • Cofactor 76%
  • Blood Cells 68%
  • Acids 62%
  • Cell Line 49%